Oncolys BioPharma Inc. (4588) Other
Market cap
¥73.3B
P/E ratio
Develops viral therapies for cancer treatment and severe infections, with lead candidate OBP-301 targeting solid tumors like esophageal cancer.
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Return on Assets | - | - | - | - | -5.7 | -5.6 | -9.3 | -9.5 | -8.2 | -15.3 | -17.9 | -9 | -28.4 | -16.7 | -11.4 |
| Return on equity (%) | - | - | - | ||||||||||||
| Employees | 11 | 20 | 22 | 28 | 29 | 30 | 29 | 30 | 27 | 32 | 33 | 33 | 34 | 35 | 38 |